Levi & Korsinsky Alerts Geron Corporation Investors of Class Action Lawsuit

Levi & Korsinsky has alerted investors of Geron Corporation about an impending class action lawsuit and the approaching deadline to take action. The law firm is informing shareholders about the legal proceedings involving Geron Corporation stock.

Geron Corporation, a biopharmaceutical company, is facing a class action lawsuit initiated on behalf of shareholders who acquired Geron stock between March 19, 2018, and September 26, 2018. The lawsuit alleges that Geron made false and misleading statements about its flagship drug, imetelstat, during the time frame specified.

Imetelstat is Geron’s main drug candidate that is being developed to treat essential thrombocythemia and myelofibrosis. The class action lawsuit claims that Geron misrepresented the results of clinical trials for imetelstat, leading to inflated stock prices. When the truth about the drug’s efficacy and success in clinical trials came to light, Geron’s stock prices plummeted, causing financial losses for investors.

Investors who purchased Geron Corporation stock during the mentioned period are urged to take part in the class-action lawsuit before the deadline expires. By participating in the legal proceedings, affected shareholders can potentially recover financial losses suffered due to the alleged misconduct by Geron Corporation.

It is essential for investors to be aware of their rights and options in such situations. Levi & Korsinsky is offering legal assistance to investors who wish to join the class-action lawsuit against Geron Corporation. Shareholders who believe they have incurred losses as a result of the misrepresentation of imetelstat’s clinical trial results are encouraged to take action before the deadline.

Class action lawsuits provide shareholders with a collective legal recourse against companies alleged to have engaged in fraudulent or deceptive practices that led to financial harm. By pooling resources and experiences, affected investors can seek to hold the company accountable for any misrepresentations or misconduct.

Investors who wish to participate in the class-action lawsuit against Geron Corporation should act promptly to ensure they meet the filing deadline. Seeking legal counsel and understanding one’s rights as a shareholder are crucial steps in seeking justice and potential financial recovery in cases of alleged corporate wrongdoing.

The class action lawsuit against Geron Corporation underscores the importance of transparency and accuracy in the biopharmaceutical industry. Shareholders deserve truthful and reliable information about the companies in which they invest, and any discrepancies or misrepresentations should be addressed through legal channels to protect investors’ rights and interests.